DMAC - CIK 0001401040
The table below shows DiaMedica Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $7.99M | $6.44M | $5.82M | $5.66M | $4.98M | $3.93M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.50M |
| $2.60M |
| $2.19M |
| $2.49M |
| $1.90M |
| $1.71M |
| Operating income | -$10.48M | -$9.03M | -$8.01M | -$8.14M | -$6.88M | -$5.64M |
| Income tax | $7.00K | $6.00K | $6.00K | $6.00K | $7.00K | $7.00K |
| Net income | -$10.04M | -$8.62M | -$7.70M | -$7.71M | -$6.27M | -$5.12M |
| EPS (diluted) | - | - | - | - | - | - |